Summary

Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032


Market Overview
It is anticipated that the Middle East and Africa Human Vaccine Market will experience a robust compound annual growth rate (CAGR) of 8.80% during the review period. The immune system is stimulated to produce immunity to a specific disease by biological preparations known as human vaccines, which protect individuals from infection and its potentially severe consequences. These vaccines typically contain attenuated or inactivated forms of pathogens (such as viruses or bacteria), their toxins, or surface proteins, which elicit an immune response without causing the disease.
The rise in disease burden and epidemic outbreaks, as well as the growing awareness of the significance of vaccination in the prevention of infectious diseases, are driving the expansion of the human vaccine market in the Middle East and Africa. In addition, the market will develop development opportunities in the future because of the growing funding and investment in expansion.

Market Segment Insights
The Middle East & Africa Human Vaccine Market has been segmented into the following categories: Inactivated, Toxoid, Conjugate and Subunit, and Recombinant DNA.This organization is based on the type of vaccine.

The Market has been segmented into Adults and Pediatrics based on age. The Pediatrics segment was the largest market in 2023 and the fastest-growing segment during the forecast period.
The Middle East & Africa Human Vaccine Market has been segmented into Pneumococcal, Influenza, Hepatitis, DTP, Polio, and other categories based on indication.
The Market has been segmented into Injectable, Oral, and Other based on the Route of Administration.
The market has been divided into Public and Private based on the distribution channel.
In 2023, the market was worth USD Egypt million. The Middle East is further divided into the following subregions: the United Arab Emirates (UAE), Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East.
The human vaccine market in the Middle East is poised for substantial development, because of the growing awareness of the significance of vaccination, rising healthcare expenditure, and heightened governmental support for vaccination. In April 2024, the Kingdom of Saudi Arabia committed $500 million over a five-year period to the Global Polio Eradication Initiative (GPEI). The market's expansion is additionally supported by the introduction of new vaccines that target a broader variety of diseases and advancements in vaccine technology. The current trends suggest a transition to personalized vaccines and a heightened investment in research and development to address the emergence of infectious diseases.

Major Players
Pfizer Inc, Vacsera, Merck & Co., Inc., AstraZeneca, SaudiVax, Cipla, GSK Plc, Sanofi, Biovac, Bharat Biotech, and AstraZeneca are the primary participants in the Middle East Human Vaccine Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 20
2 MARKET INTRODUCTION 22
2.1 DEFINITION 22
2.2 SCOPE OF THE STUDY 22
2.3 RESEARCH OBJECTIVE 22
2.4 MARKET STRUCTURE 23
3 RESEARCH METHODOLOGY 24
3.1 OVERVIEW 24
3.2 DATA FLOW 26
3.2.1 DATA MINING PROCESS 26
3.3 PURCHASED DATABASE: 27
3.4 SECONDARY SOURCES: 28
3.4.1 SECONDARY RESEARCH DATA FLOW: 29
3.5 PRIMARY RESEARCH: 30
3.5.1 PRIMARY RESEARCH DATA FLOW: 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 32
3.6.1 REVENUE ANALYSIS APPROACH 32
3.7 DATA FORECASTING 33
3.7.1 DATA FORECASTING TYPE 33
3.8 DATA MODELING 34
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 34
3.8.2 DATA MODELING: 35
3.9 TEAMS AND ANALYST CONTRIBUTION 37
3.10 38
4 MARKET DYNAMICS 39
4.1 INTRODUCTION 39
4.2 DRIVERS 40
4.2.1 INCREASING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION IN PREVENTING INFECTIOUS DISEASES 40
4.2.2 RISING DISEASE BURDEN AND EPIDEMIC OUTBREAKS 40
4.2.3 RISING STRATEGIC INITIATIVES ASSOCIATED WITH VACCINE IN MIDDLE EAST & AFRICA 40
4.3 RESTRAINTS 41
4.3.1 STRINGENT REGULATORY POLICIES 41
4.4 OPPORTUNITY 43
4.4.1 INCREASING FUNDING AND INVESTMENT FOR EXPANSION 43
5 MARKET FACTOR ANALYSIS 44
5.1 PORTER'S FIVE FORCES MODEL 44
5.1.1 THREAT OF NEW ENTRANTS 45
5.1.2 BARGAINING POWER OF SUPPLIERS 45
5.1.3 BARGAINING POWER OF BUYERS 45
5.1.4 THREAT OF SUBSTITUTES 45
5.1.5 INTENSITY OF RIVALRY 45
5.2 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA HUMAN VACCINES MARKET 46
6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE 48
6.1 OVERVIEW 48
6.2 INACTIVATED 50
6.3 TOXOID 51
6.4 CONJUGATE AND SUBUNIT 51
6.5 RECOMBINANT DNA 51
7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP 52
7.1 OVERVIEW 52
7.2 PEDIATRICS 54
7.3 ADULTS 54
8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION 55
8.1 OVERVIEW 55
8.2 PNEUMOCOCCAL 58
8.3 INFLUENZA 58
8.4 HEPATITIS 58
8.4.1 HEPATITIS A 59
8.4.2 HEPATITIS B 60
8.5 DTP 60
8.6 POLIO 61
8.6.1 INACTIVATED POLIO VACCINE (IPV) 62
8.6.2 ORAL POLIO VACCINE (OPV) 62
8.7 HUMAN PAPILLOMAVIRUS 62
8.8 MENINGOCOCCAL 63
9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 64
9.1 OVERVIEW 64
9.2 INJECTABLE 67
9.3 ORAL 67
9.4 OTHERS 67
10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 68
10.1 OVERVIEW 68
10.2 PUBLIC 70
10.3 PRIVATE 70
11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION 71
11.1 MIDDLE EAST 72
11.1.1 UAE 79
11.1.2 SAUDI ARABIA 83
11.1.3 ISRAEL 87
11.1.4 KUWAIT 91
11.1.5 OMAN 96
11.1.6 QATAR 99
11.1.7 EGYPT 102
11.1.8 BAHRAIN 106
11.1.9 REST OF MIDDLE EAST 109
11.2 AFRICA 113
11.2.1 KENYA 119
11.2.2 SOUTH AFRICA 122
11.2.3 NIGERIA 126
11.2.4 MOZAMBIQUE 129
11.2.5 TANZANIA 132
11.2.6 UGANDA 136
11.2.7 MOROCCO 139
11.2.8 REST OF AFRICA 143
12 COMPETITIVE LANDSCAPE 148
12.1 INTRODUCTION 148
12.2 MARKET SHARE ANALYSIS, 2023 (%) 148
12.3 COMPETITOR DASHBOARD 149
12.4 PUBLIC PLAYERS STOCK SUMMARY 150
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 150
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 151
12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 151
12.6.2 AGREEMENT/COLLABORATION/PARTNERSHIP 151
13 COMPANY PROFILES 152
13.1 SANOFI 152
13.1.1 COMPANY OVERVIEW 152
13.1.2 FINANCIAL OVERVIEW 153
13.1.3 PRODUCTS OFFERED 153
13.1.4 KEY DEVELOPMENTS 154
13.1.5 SWOT ANALYSIS 155
13.1.6 KEY STRATEGIES 155
13.2 BHARAT BIOTECH 156
13.2.1 COMPANY OVERVIEW 156
13.2.2 FINANCIAL OVERVIEW 157
13.2.3 PRODUCTS OFFERED 157
13.2.4 KEY DEVELOPMENTS 157
13.2.5 KEY STRATEGIES 157
13.3 PFIZER INC 158
13.3.1 COMPANY OVERVIEW 158
13.3.2 FINANCIAL OVERVIEW 159
13.3.3 PRODUCTS OFFERED 159
13.3.4 KEY DEVELOPMENTS 160
13.3.5 SWOT ANALYSIS 160
13.3.6 KEY STRATEGIES 161
13.4 MERCK & CO., INC. 162
13.4.1 COMPANY OVERVIEW 162
13.4.2 FINANCIAL OVERVIEW 163
13.4.3 PRODUCTS OFFERED 164
13.4.4 KEY DEVELOPMENTS 164
13.4.5 KEY STRATEGIES 164
13.5 ASTRAZENECA 165
13.5.1 COMPANY OVERVIEW 165
13.5.2 FINANCIAL OVERVIEW 166
13.5.3 PRODUCTS OFFERED 166
13.5.4 KEY DEVELOPMENTS 167
13.5.5 KEY STRATEGIES 167
13.6 CIPLA 168
13.6.1 COMPANY OVERVIEW 168
13.6.2 FINANCIAL OVERVIEW 169
13.6.3 PRODUCTS OFFERED 169
13.6.4 KEY DEVELOPMENTS 169
13.6.5 SWOT ANALYSIS 170
13.6.6 KEY STRATEGIES 170
13.7 SAUDIVAX 171
13.7.1 COMPANY OVERVIEW 171
13.7.2 FINANCIAL OVERVIEW 172
13.7.3 PRODUCTS OFFERED 172
13.7.4 KEY DEVELOPMENTS 172
13.7.5 KEY STRATEGIES 172
13.8 GSK PLC 173
13.8.1 COMPANY OVERVIEW 173
13.8.2 FINANCIAL OVERVIEW 174
13.8.3 PRODUCT OFFERED 175
13.8.4 KEY DEVELOPMENTS 175
13.8.5 SWOT ANALYSIS 176
13.8.6 KEY STRATEGIES 176
13.9 BIOVAC 177
13.9.1 COMPANY OVERVIEW 177
13.9.2 FINANCIAL OVERVIEW 178
13.9.3 PRODUCTS OFFERED 178
13.9.4 KEY DEVELOPMENTS 178
13.9.5 KEY STRATEGIES 178
13.10 VACSERA 179
13.10.1 COMPANY OVERVIEW 179
13.10.2 FINANCIAL OVERVIEW 179
13.10.3 PRODUCTS OFFERED 179
13.10.4 KEY DEVELOPMENTS 180
13.10.5 KEY STRATEGIES 180
14 DATA CITATIONS 181